2LEBV® and 2LXFS® for Epstein-Barr Virus Infection

Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection

Recruiting Phase 4 Interventional Study
EBV Infection
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
12 and older
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
88 (estimated)
Sponsor
Labo'Life · Industry
Who this trial is looking for

This trial is looking for patients aged 12 and older who experience fatigue and other related symptoms due to Epstein-Barr Virus (EBV) infection. Participants will take one capsule of the treatment each day for six months.

Are You a Good Fit for This Trial?
Rules you out Severe immunodeficiency disease

You may be able to join if

  • I am aged 12 years or older.
  • I have fatigue lasting for at least 1 month.
  • I have at least two additional symptoms related to EBV.
  • I have a positive test for EBV infection.

You may not be able to join if

  • I have received treatment with 2LEBV® or 2LXFS® before.
  • I have taken homeopathic treatments in the last 2 months.
  • I am currently on immunosuppressive treatment.
  • I am undergoing treatment for psychiatric disorders.
  • I have severe immunodeficiency disease.
  • I am pregnant or breastfeeding.
  • I participated in another clinical study in the last 2 months.
  • I am using recreational drugs.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Worldwide, 95% of adults are infected with Epstein-Barr Virus (EBV). These infections may cause different diseases. In most cases, EBV infection is asymptomatic because of a highly effective host immune response. Some individuals develop infectious mononucleosis (a self-limiting lymphoproliferative disorder in adolescents and young adults that is considered to be the primary infection), while othe…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Pré-Inclusion Criteria: * Patients, male or female, aged 12 years and older, * Patient with fatigue for 1 month or more, * Patient with at least two other symptoms among the following: Long-lasting exhaustion even after light exertion, subfebrile state, fever, loss of appetite, nausea, angina, conj…
Contacts

Charlotte BOLLE

497 49 13 74

charlotte.bolle@labolife.com

CONTACT

Laura FERTE

499 71 79 64

laura.ferte@labolife.com

CONTACT